Based in Dallas and Nashville, Pharos Capital Group is a physician-founded private equity firm focused on growing healthcare companies which lower the total cost of care, improve patient outcomes and expand access to care. Pharos invests to reduce healthcare inequalities in underserved markets across the United States, especially within urban and rural communities. Since inception, Pharos has invested in 57 companies and currently has over $1.1 billion of assets under management as of March 31st, 2022. Pharos typically invests $25-$50 million in rapidly growing middle market companies seeking later stage funding for internal growth, acquisitions, leveraged buyouts, management buyouts, or recapitalizations.
Leadership
| Name | Title | ||
|---|---|---|---|
| Kneeland Youngblood | CEO |
|
|
| Chief Investment Officer |
|
|
|
| Partner |
|
|
|
| Partner |
|
|
|
| Partner |
|
|
|
| Principal |
|
|
|
| Vice President |
|
|
|
| Vice President |
|
|
Recent Transactions involving Pharos Capital Group
| Deal | Target | Platform | Buyer | Industry |
|---|---|---|---|---|
Pharos Capital Makes Majority Investment in RhythMedix |
RhythMedix |
Pharos Capital Group |
Cardiac Monitoring Devices | |
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Lower and Middle Market M&A Platform
See how PrivSource can help you close more deals.
Learn more →